Duke joins Johns Hopkins Hospital which is already conducting the Phase I trial of NPC-1C. In addition to Johns Hopkins, North Shore – LIJ has also enrolled patients on this multi-center study.
NPC-1C is a novel, chimeric monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer, and is the first of the Neogenix pipeline of antibodies that target specific cancers, the company said.
Pre-clinical studies have demonstrated that NPC-1C specifically targets pancreatic and colorectal cancer sparing healthy tissue.
Neogenix CEO Philip Arlen said that they look forward to fostering the relationships with both of these prestigious medical establishments for future Neogenix therapeutic development.